<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Talphera Inc. — News on 6ix</title>
<link>https://6ix.com/company/talphera-inc</link>
<description>Latest news and press releases for Talphera Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/talphera-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ca1978dffbe2df11c95a.webp</url>
<title>Talphera Inc.</title>
<link>https://6ix.com/company/talphera-inc</link>
</image>
<item>
<title>Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-two-abstracts-accepted-for-presentation-at-aki-and-crrt-2026</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-two-abstracts-accepted-for-presentation-at-aki-and-crrt-2026</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development</description>
</item>
<item>
<title>Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1</description>
</item>
<item>
<title>Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-to-host-virtual-investor-and-analyst-event-to-discuss-niyadr-for-use-in-continuous-renal-replacement-therapy-crrt-on-march-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-to-host-virtual-investor-and-analyst-event-to-discuss-niyadr-for-use-in-continuous-renal-replacement-therapy-crrt-on-march-23-2026</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development</description>
</item>
<item>
<title>Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-50percent-enrollment-milestone-in-ongoing-nephro-crrt-registrational-trial</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-50percent-enrollment-milestone-in-ongoing-nephro-crrt-registrational-trial</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial.</description>
</item>
<item>
<title>Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-third-quarter-2025-210500819</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-third-quarter-2025-210500819</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2025 financial results and provided a corporate update.</description>
</item>
<item>
<title>Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-host-third-quarter-financial-210500421</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-host-third-quarter-financial-210500421</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.</description>
</item>
<item>
<title>Talphera Announces the Appointment of Joe Todisco to Board of Directors</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-appointment-joe-todisco-123000076</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-appointment-joe-todisco-123000076</guid>
<pubDate>Tue, 21 Oct 2025 12:30:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (Nasdaq: CRMD) to its Board of Directors.</description>
</item>
<item>
<title>Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-private-placement-financing-123000712</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-private-placement-financing-123000712</guid>
<pubDate>Mon, 08 Sep 2025 12:30:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into securities purchase agreements with CorMedix Inc. and certain institutional investors for the sale and issuance of shares of common stock and pre-funded warrants in lieu of shares to purchase common stock in a private placement for total potential proceeds of up to $29 m</description>
</item>
<item>
<title>CorMedix Announces Strategic Minority Investment in Talphera</title>
<link>https://6ix.com/company/talphera-inc/news/cormedix-announces-strategic-minority-investment-in-talphera</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/cormedix-announces-strategic-minority-investment-in-talphera</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-achievement-17-patient-123000126</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-achievement-17-patient-123000126</guid>
<pubDate>Mon, 25 Aug 2025 12:30:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the enrollment of 17 patients in its 70-patient pivotal NEPHRO CRRT clinical trial. The enrollment of 17 patients is a milestone that was required to be achieved, and announced, as one of the conditions to close the second tranche of the three-tranche financing announced in March 2025.</description>
</item>
<item>
<title>Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-second-quarter-2025-200500746</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-second-quarter-2025-200500746</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update.</description>
</item>
<item>
<title>Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-host-second-quarter-financial-203500704</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-host-second-quarter-financial-203500704</guid>
<pubDate>Thu, 07 Aug 2025 20:35:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.</description>
</item>
<item>
<title>Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-first-quarter-2025-200500999</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-first-quarter-2025-200500999</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial results and provided a corporate update.</description>
</item>
<item>
<title>Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-host-first-quarter-financial-200500754</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-host-first-quarter-financial-200500754</guid>
<pubDate>Wed, 07 May 2025 20:05:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.</description>
</item>
<item>
<title>Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-fourth-quarter-full-200500972</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-fourth-quarter-full-200500972</guid>
<pubDate>Mon, 31 Mar 2025 20:05:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2024 financial results and provided a corporate update.</description>
</item>
<item>
<title>Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-agreement-fda-reduce-123000251</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-agreement-fda-reduce-123000251</guid>
<pubDate>Mon, 31 Mar 2025 12:30:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously included in the study protocol. The Company also announced it has entered into securities purchase agreements with certain institutional investors and a member of management for the</description>
</item>
<item>
<title>Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-host-fourth-quarter-full-203800902</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-host-fourth-quarter-full-203800902</guid>
<pubDate>Wed, 26 Mar 2025 20:38:00 GMT</pubDate>
<description>Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.</description>
</item>
<item>
<title>Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-agreement-with-the-fda-for-prior-approval-supplement-review-to-reduce-the-number-of-patients-in-the-nephro-crrt-study</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-agreement-with-the-fda-for-prior-approval-supplement-review-to-reduce-the-number-of-patients-in-the-nephro-crrt-study</guid>
<pubDate>Tue, 14 Jan 2025 05:00:00 GMT</pubDate>
<description>Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed</description>
</item>
<item>
<title>Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors</title>
<link>https://6ix.com/company/talphera-inc/news/ascentage-pharma-appoints-ms-marina-s-bozilenko-and-dr-debra-yu-as-independent-non-executive-directors</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/ascentage-pharma-appoints-ms-marina-s-bozilenko-and-dr-debra-yu-as-independent-non-executive-directors</guid>
<pubDate>Sun, 24 Nov 2024 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering,</description>
</item>
<item>
<title>Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/talphera-inc/news/talphera-announces-third-quarter-2024-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/talphera-inc/news/talphera-announces-third-quarter-2024-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 13 Nov 2024 05:00:00 GMT</pubDate>
<description>Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter</description>
</item>
</channel>
</rss>